View in browser
A teal and orange overlapping shape with "ppa" in white is on the left, and "pheopara ALLIANCE" in teal is on the right, all on a white background.

Pheo Para Navigator

October 2026

Research | Clinical Care | Community | Progress

Welcome to the Pheo Para Alliance's monthly newsletter.

round gray framed compass on brown map

Dear Pheo Para Community Member,


October has brought encouraging developments in PPGL research and treatment, new opportunities to work with our international partners, and some heartbreaking losses within our community.


In this edition, I want to share where we are with our Global Pheo Para Patient and Provider Registry, news about another international approval of WELIREG, and ways you can participate in upcoming educational and awareness activities.


We also remember Professor Mario Sanna and Jenifer Hunt, two remarkable people who meant so much to our Pheo Para family.


Thank you for being part of this community and for the many ways you support one another and our work.


With gratitude,


Dr. JoBeth McCarthy, DHSc, MPH, CPH
Executive Director
Pheo Para Alliance

jobeth@pheopara.org


Remembering Two Remarkable Members of Our Pheo Para Family

Two portrait photos of Professor Mario Sanna and Jenifer Hunt flank a central lit candle against a black background with memorial text.

This month, we mourn the loss of Professor Mario Sanna and Jenifer Hunt, two remarkable people whose compassion and dedication touched lives throughout our community.


Professor Mario Sanna was an internationally renowned surgeon and pioneer in skull base surgery whose expertise helped transform care for people living with head and neck paragangliomas. As Founder and Director of Gruppo Otologico in Italy, he devoted his career to improving surgical care, mentoring physicians, and bringing experts together across borders. We were fortunate to have him share his knowledge with our Pheo Para community. He will be remembered not only for his extraordinary contributions to medicine, but for his generosity, friendship, and humanity.


Jenifer Hunt was our beloved PPA Care Kit Manager, Peer Navigator, and Peer Support Meeting Facilitator. She personally prepared Care Kits for people newly diagnosed with PPGL or learning they carried a related genetic variant, often including a handwritten note to remind someone she had never met that they were not alone. She also gave generously of her time to help patients and families navigate difficult conversations, find support, and connect with others who understood. Her kindness reached people around the world, and the care she showed them will not be forgotten.


We are heartbroken by these losses, and our thoughts remain with their families, friends, colleagues, and everyone who knew and loved them.


Help Us Remember Professor Mario Sanna and Jenifer Hunt

We invite you to share a memory, a message of gratitude, or a few words of comfort for their families. Whether you knew them personally or were touched by their work, your words will help us celebrate their lives and the difference they made.


We have invited our community to share memories and messages of condolence through our social media tributes. If Professor Sanna or Jenifer touched your life, I hope you will consider sharing a memory or a few words of support for their families.


Patient Pathways

Your Roadmap From Diagnosis to Care: October 28

Finding experienced care and reliable information remains a challenge for many people living with pheochromocytoma and paraganglioma (PPGL).


On Wednesday, October 28, from 1:00–2:30 PM ET, PPA will host Pheochromocytoma and Paraganglioma: Your Roadmap From Diagnosis to Care, a free educational webinar featuring international PPGL experts.


Dr. Karel Pacak, Professor Ali Alzahrani, Professor Svenja Nölting, and Siobhan Farley, RN and Pheo Para Alliance Peer Navigator, will share their expertise on diagnosis, treatment considerations, and long-term management.


Whether you have recently been diagnosed, are navigating ongoing care, or are supporting someone you love, we hope you will join us.


Thank you to Novartis for supporting this educational program.


Research & Registry

Building a Global Research Resource for the Full Spectrum of PPGL: Our October Update

Our Global Pheo Para Patient and Provider Registry is moving forward, with patients, caregivers, clinicians, and researchers helping shape its development through PPA's Research and Registry Advisory Board (RRAB).


This month, we reached two important milestones. We submitted our initial research protocol and study aims to the National Organization for Rare Disorders (NORD), and we are now reviewing the data dictionary—the information the registry will collect and how it will be organized.


The registry is being designed to connect patient experiences with genetic and clinical information, treatment histories, and long-term outcomes from around the world. Our goal is to better understand the full spectrum of PPGL, including hereditary risk, localized and recurrent tumors, and metastatic cancer.


We want to hear from you.

What questions about PPGL do you most hope research will answer? What do you wish researchers better understood about living with PPGL or carrying a genetic variant that increases your risk?


Your perspectives matter as we develop this global research resource. We welcome your thoughts and will share them with our research leadership as the registry takes shape.


The registry is being developed on NORD's IAMRARE platform, with a planned launch in 2027. Enrollment has not yet begun.


Thank you to our RRAB members and everyone helping make this important work possible.


Research Compass

WELIREG: An International Treatment Update

China Approves WELIREG (Belzutifan) for Advanced PPGL

China's National Medical Products Administration (NMPA) approved WELIREG (belzutifan) on October 22, 2026, for adults and adolescents aged 12 and older with locally advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL).


For people whose tumors cannot be surgically removed or have spread to other parts of the body, this is an important development. PPGLs are rare neuroendocrine tumors that can cause serious, sometimes life-threatening complications, and treatment options for advanced disease remain limited.


Recognizing the Patients, Science, and People Behind This Milestone

At the heart of this achievement are the patients and families who made clinical research possible. Participating in a clinical trial requires time, trust, and a willingness to navigate uncertainty. For people living with a rare disease, that commitment carries particular significance.


We extend our deepest gratitude to every patient who participated in LITESPARK-015 and to the families and caregivers who supported them. Their contributions helped generate the evidence needed to expand treatment options for people living with advanced PPGL.


This approval also reflects years of scientific discovery, clinical investigation, and international collaboration. We congratulate Merck and the international team of scientists, clinicians, and investigators whose work contributed to this milestone. We especially recognize Dr. Camilo Jimenez of MD Anderson Cancer Center and Dr. Jaydira Del Rivero of the National Cancer Institute, both members of PPA's Medical Advisory Board and coauthors of the published LITESPARK-015 study.


This milestone belongs not only to the scientific community, but also to the patients whose participation made it possible.


What Does the Research Show?

China's approval follows the publication of findings from the international phase 2 LITESPARK-015 clinical trial in the New England Journal of Medicine in October 2025. The study evaluated belzutifan in 72 patients with locally advanced or metastatic PPGL that was not amenable to surgery or curative-intent treatment.


Researchers Reported:

  • 26% objective response rate: About one in four participants experienced measurable tumor shrinkage that met the study's criteria for a confirmed response.
  • 85% disease control rate: Approximately 85% of participants had tumors that either responded to treatment or remained stable according to the study's assessment criteria.
  • 20.4 months median duration of response: Among participants whose tumors responded, half had responses lasting longer than this period and half had shorter responses.

These findings demonstrate meaningful antitumor activity in some patients, although not everyone benefits from treatment.


How Does Belzutifan Work?

Belzutifan is an oral targeted therapy that inhibits hypoxia-inducible factor 2 alpha (HIF-2α), a protein involved in how cells respond to oxygen levels.


Abnormal activity in this pathway can contribute to the development and growth of certain PPGL tumors. By inhibiting HIF-2α, belzutifan interferes with signals that may support tumor growth and new blood vessel formation.


What Does This Mean for Patients?

Belzutifan received U.S. Food and Drug Administration approval for advanced PPGL in May 2025. China's approval represents another important regulatory milestone for the international PPGL community.


Although approval expands treatment possibilities, access may still depend on local availability, reimbursement, and individual clinical circumstances.


Belzutifan also carries significant risks, including anemia, low blood oxygen levels, and potential harm during pregnancy. Patients should discuss its potential benefits and risks with a clinical team experienced in PPGL care.


For the Pheo Para Alliance, this milestone reinforces the importance of sustained investment in rare disease research, international collaboration, and ensuring that scientific discoveries translate into meaningful treatment options for people living with PPGL.


Learn More About Belzutifan

Want to better understand how belzutifan works and what the clinical research means for people living with advanced PPGL?


Watch Pheo Para Alliance's educational webinar featuring Dr. Camilo Jimenez of MD Anderson Cancer Center, a LITESPARK-015 investigator and member of our Medical Advisory Board. Dr. Jimenez discusses the science behind belzutifan, the clinical trial findings, and important considerations for patients and their care teams.


Finding Experienced Care

Connecting Patients and Providers with PPGL Expertise

A circular logo for the "PHEO PARA ALLIANCE Center of Excellence Program" is centered against a solid teal background.

Pheo Para Alliance recognizes 20+ Centers of Excellence (COEs) worldwide, bringing together multidisciplinary teams experienced in PPGL diagnosis, treatment, and long-term care.


Patients and caregivers can explore our global COE directory, while healthcare professionals and institutions are invited to learn about COE recognition and referral partnerships.


FIND A CENTER OF EXCELLENCE


HEALTHCARE PROFESSIONALS


Science, Community & Hope

NET Cancer Day 2026: SUSPECT. DETECT.

White text reading "Suspect. Detect." and "NET Cancer Day November 10 2026" sits in the foreground against a dark grey background featuring the INCA logo and a zebra-patterned circle.

November 10, 2026 | A Global Campaign Led by INCA

Pheo Para Alliance is proud to join our partners at the International Neuroendocrine Cancer Alliance (INCA) in recognizing NET Cancer Day on November 10.


Created by INCA more than a decade ago, NET Cancer Day brings together patients, caregivers, healthcare professionals, researchers, and advocacy organizations worldwide to improve awareness of neuroendocrine cancer and the need for timely diagnosis and equitable access to care.


This year's campaign, SUSPECT. DETECT., focuses on recognizing symptoms that may be mistaken for more common conditions and the importance of considering neuroendocrine tumors earlier in the diagnostic process.


This message is particularly relevant to the PPGL community. Our research has documented the consequences of missed and delayed diagnoses, including patients who experienced symptoms for years before receiving an accurate diagnosis. Others may have few or no symptoms, making awareness and appropriate clinical evaluation equally important.


As an INCA member, PPA supports the global campaign while highlighting the unique diagnostic challenges associated with PPGL.

How You Can Participate

INCA has developed an excellent collection of free resources that patients, caregivers, advocates, and healthcare professionals can use to help spread awareness. Download the resources and join the global NET Cancer Day on Nov. 10.



Building the Registry Together

The Global Pheo Para Patient & Provider Registry is being built for our community, and our community is making it possible.


We are deeply grateful to everyone who has helped bring this important research resource to life. Whether you gave in honor of someone you love, in memory of someone you miss, or because you believe in the future of PPGL research, you are helping build that future.


Thank you to our Registry supporters.

Instagram
Facebook
X
TikTok
LinkedIn

The Pheo Para Alliance's mission is to empower patients with pheochromocytoma or paraganglioma, their families, and medical professionals through advocacy, education, and a global community of support, while advancing research that accelerates treatments and cures.


Patients, caregivers, clinician-scientists, and advocates founded us in 2007. The Pheo Para Alliance is a registered 501(c)(3) nonprofit organization, incorporated in the state of Virginia. Tax ID: 26-1510652.